From Glioblastoma Treatments
Jump to navigationJump to search
|
|
| Line 1: |
Line 1: |
| {{TreatmentInfo
| | |
| |drug_name=Melatonin
| |
| |FDA_approval=No
| |
| |used_for=Glioblastoma Multiforme (GBM), insomnia, jet lag
| |
| |clinical_trial_phase=Mixed (Phase 2 and Phase 3 trials mentioned)
| |
| |common_side_effects=No known toxic side effects
| |
| |OS_without=Survival significantly greater in melatonin-treated subjects in small GBM study
| |
| |OS_with=Increases efficacy of chemotherapy; significant survival benefit observed in various cancers
| |
| |PFS_without=Not specified
| |
| |PFS_with=Not specified
| |
| |usefulness_rating=4
| |
| |notes=Melatonin has shown promise in clinical trials, primarily in Italy, used both as a single agent and in combination with chemotherapy or immunotherapy. Significant increases in survival rates have been observed in trials for GBM, lung cancer, and other cancers. Melatonin not only increased the efficacy of chemotherapy but also significantly reduced its toxicity.
| |
| |category=Hormones
| |
| |links=
| |
| * [Link to study on Melatonin and GBM](https://pubmed.ncbi.nlm.nih.gov/35395355)
| |
| * [Link to review on therapeutic strategies for GBM](#)
| |
| * [Link to clinical trial results of Melatonin use in cancer treatment](#)
| |
| |toxicity_level=3
| |
| }}
| |
Revision as of 09:29, 27 March 2024
